(Pro)renin receptor and insulin resistance: Possible roles of angiotensin II-dependent and -independent pathways

Molecular and Cellular Endocrinology

Volumn 378, Issue 1-2, 2013, Pages 41-45

  Rafiq, Kazi ^a   Mori, Hirohito ^a   Masaki, Tsutomu ^a   Nishiyama, Akira ^a  

^a KAGAWA UNIVERSITY   (Japan)

Author keywords

(Pro)renin receptor (P)RR ; Aliskiren; Insulin resistance; Prorenin; Renin

Indexed keywords

ANGIOTENSIN II; ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HANDLE REGION DECOY PEPTIDE; PRORENIN RECEPTOR; UNCLASSIFIED DRUG;

ADIPOSE TISSUE; CARDIOVASCULAR DISEASE; DIABETES MELLITUS; GENE; GENE DELETION; GENE MUTATION; GENE OVEREXPRESSION; GLUCOSE INTOLERANCE; HUMAN; HYPERTENSION; INSULIN RESISTANCE; INTRACELLULAR SIGNALING; KIDNEY INJURY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OTSUKA LONG EVANS TOKUSHIMA FATTY RAT; PATHOGENESIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN INDUCTION; PROTEIN SYNTHESIS; PRR GENE; REVIEW; SKELETAL MUSCLE;

(PRO)RENIN RECEPTOR [(P)RR]; ALISKIREN; INSULIN RESISTANCE; PRORENIN; RENIN;

ANGIOTENSIN II; ANIMALS; GLUCOSE INTOLERANCE; HUMANS; INSULIN RESISTANCE; MUSCLE, SKELETAL; OLIGOPEPTIDES; PROTON-TRANSLOCATING ATPASES; RATS; RATS, INBRED OLETF; RECEPTORS, CELL SURFACE; SIGNAL TRANSDUCTION; VACUOLAR PROTON-TRANSLOCATING ATPASES;

EID: 84884534005     PISSN: 03037207     EISSN: 18728057     Source Type: Journal    
DOI: 10.1016/j.mce.2012.05.016     Document Type: Review

References (68)

1. Achard V., Boullu-Ciocca S., Desbriere R., Nguyen G., Grino M. Renin receptor expression in human adipose tissue. Am J Physiol Regul Integr Comp Physiol. 2007, 292:R274-282.
2. Advani A., Kelly D.J., Cox A.J., White K.E., Advani S.L., Thai K., Connelly K.A., Yuen D., Trogadis J., Herzenberg A.M., Kuliszewski M.A., Leong-Poi H., Gilbert R.E. The (Pro)renin receptor: site-specific and functional linkage to the vacuolar H+-ATPase in the kidney. Hypertension 2009, 54:261-269.
3. Amsterdam A., Nissen R.M., Sun Z., Swindell E.C., Farrington S., Hopkins N. Identification of 315 genes essential for early zebrafish development. Proc. Natl. Acad. Sci. USA 2004, 101:12792-12797.
4. Arakawa K., Nakatani M., Nakamura M. Species specificity in reaction between renin and angiotensinogen. Nature 1965, 207:636.
5. Balakumar P., Jagadeesh G. Potential cross-talk between (pro)renin receptors and Wnt/frizzled receptors in cardiovascular and renal disorders. Hypertens. Res. 2011, 34:1161-1170.
6. Batenburg W.W., Krop M., Garrelds I.M., de Vries R., de Bruin R.J., Burckle C.A., Muller D.N., Bader M., Nguyen G., Danser A.H. Prorenin is the endogenous agonist of the (pro)renin receptor. Binding kinetics of renin and prorenin in rat vascular smooth muscle cells overexpressing the human (pro)renin receptor. J. Hypertens. 2007, 25:2441-2453.
7. Biswas K.B., Nabi A.H., Arai Y., Nakagawa T., Ebihara A., Ichihara A., Watanabe T., Inagami T., Suzuki F. Aliskiren binds to renin and prorenin bound to (pro)renin receptor in vitro. Hypertens. Res. 2010, 33:1053-1059.
8. Burckle C., Bader M. Prorenin and its ancient receptor. Hypertension 2006, 48:549-551.
9. Campbell D.J., Karam H., Menard J., Bruneval P., Mullins J.J. Prorenin contributes to angiotensin peptide formation in transgenic rats with rat prorenin expression targeted to the liver. Hypertension 2009, 54:1248-1253.
10. Choi Y.O., Park J.H., Song Y.S., Lee W., Moriyama Y., Choe H., Leem C.H., Jang Y.J. Involvement of vesicular H+-ATPase in insulin-stimulated glucose transport in 3T3-F442A adipocytes. Endocr. J. 2007, 54:733-743.
11. Dong Y.F., Liu L., Kataoka K., Nakamura T., Fukuda M., Tokutomi Y., Nako H., Ogawa H., Kim-Mitsuyama S. Aliskiren prevents cardiovascular complications and pancreatic injury in a mouse model of obesity and type 2 diabetes. Diabetologia 2010, 53:180-191.
12. Feldt S., Batenburg W.W., Mazak I., Maschke U., Wellner M., Kvakan H., Dechend R., Fiebeler A., Burckle C., Contrepas A., Jan Danser A.H., Bader M., Nguyen G., Luft F.C., Muller D.N. Prorenin and renin-induced extracellular signal-regulated kinase 1/2 activation in monocytes is not blocked by aliskiren or the handle-region peptide. Hypertension 2008, 51:682-688.
13. Feldt S., Maschke U., Dechend R., Luft F.C., Muller D.N. The putative (pro)renin receptor blocker HRP fails to prevent (pro)renin signaling. J. Am. Soc. Nephrol. 2008, 19:743-748.
14. Fogari R., Zoppi A., Mugellini A., Lazzari P., Derosa G. Different effects of aliskiren and losartan on fibrinolysis and insulin sensitivity in hypertensive patients with metabolic syndrome. Horm. Metab. Res. 2010, 42:892-896.
15. Gratze P., Boschmann M., Dechend R., Qadri F., Malchow J., Graeske S., Engeli S., Janke J., Springer J., Contrepas A., Plehm R., Klaus S., Nguyen G., Luft F.C., Muller D.N. Energy metabolism in human renin-gene transgenic rats: does renin contribute to obesity?. Hypertension 2009, 53:516-523.
16. Habibi J., Whaley-Connell A., Hayden M.R., DeMarco V.G., Schneider R., Sowers S.D., Karuparthi P., Ferrario C.M., Sowers J.R. Renin inhibition attenuates insulin resistance, oxidative stress, and pancreatic remodeling in the transgenic Ren2 rat. Endocrinology 2008, 149:5643-5653.
17. Hirose T., Hashimoto M., Totsune K., Metoki H., Asayama K., Kikuya M., Sugimoto K., Katsuya T., Ohkubo T., Hashimoto J., Rakugi H., Takahashi K., Imai Y. Association of (pro)renin receptor gene polymorphism with blood pressure in Japanese men: the Ohasama study. Am J Hypertens 2009, 22:294-299.
18. Hirose T., Hashimoto M., Totsune K., Metoki H., Hara A., Satoh M., Kikuya M., Ohkubo T., Asayama K., Kondo T., Kamide K., Katsuya T., Ogihara T., Izumi S., Rakugi H., Takahashi K., Imai Y. Association of (pro)renin receptor gene polymorphisms with lacunar infarction and left ventricular hypertrophy in Japanese women: the Ohasama study. Hypertens. Res. 2011, 34:530-535.
19. Huang Y., Wongamorntham S., Kasting J., McQuillan D., Owens R.T., Yu L., Noble N.A., Border W. Renin increases mesangial cell transforming growth factor-beta1 and matrix proteins through receptor-mediated, angiotensin II-independent mechanisms. Kidney Int. 2006, 69:105-113.
20. Ichihara A., Kinouchi K. Current knowledge of (pro)renin receptor as an accessory protein of vacuolar H+-ATPase. J. Renin Angiotensin Aldosterone Syst. 2011, 12:638-640.
21. Ichihara A., Hayashi M., Kaneshiro Y., Suzuki F., Nakagawa T., Tada Y., Koura Y., Nishiyama A., Okada H., Uddin M.N., Nabi A.H., Ishida Y., Inagami T., Saruta T. Inhibition of diabetic nephropathy by a decoy peptide corresponding to the "handle" region for nonproteolytic activation of prorenin. J. Clin. Invest. 2004, 114:1128-1135.
22. Ichihara A., Suzuki F., Nakagawa T., Kaneshiro Y., Takemitsu T., Sakoda M., Nabi A.H., Nishiyama A., Sugaya T., Hayashi M., Inagami T. Prorenin receptor blockade inhibits development of glomerulosclerosis in diabetic angiotensin II type 1a receptor-deficient mice. J. Am. Soc. Nephrol. 2006, 17:1950-1961.
23. Ichihara A., Kaneshiro Y., Takemitsu T., Sakoda M., Nakagawa T., Nishiyama A., Kawachi H., Shimizu F., Inagami T. Contribution of nonproteolytically activated prorenin in glomeruli to hypertensive renal damage. J. Am. Soc. Nephrol. 2006, 17:2495-2503.
24. Ichihara A., Kaneshiro Y., Takemitsu T., Sakoda M., Suzuki F., Nakagawa T., Nishiyama A., Inagami T., Hayashi M. Nonproteolytic activation of prorenin contributes to development of cardiac fibrosis in genetic hypertension. Hypertension 2006, 47:894-900.
25. Ishizawa K., Yoshizumi M., Tsuchiya K., Takishita E., Nakaya Y., Kishi K., Ebina Y., Houchi H., Minakuchi K., Tamaki T. Effects of losartan in combination with or without exercise on insulin resistance in Otsuka Long-Evans Tokushima Fatty rats. Eur. J. Pharmacol. 2001, 430:359-367.
26. Iwai M., Kanno H., Tomono Y., Inaba S., Senba I., Furuno M., Mogi M., Horiuchi M. Direct renin inhibition improved insulin resistance and adipose tissue dysfunction in type 2 diabetic KK-A(y) mice. J. Hypertens. 2010, 28:1471-1481.
27. Kaneshiro Y., Ichihara A., Takemitsu T., Sakoda M., Suzuki F., Nakagawa T., Hayashi M., Inagami T. Increased expression of cyclooxygenase-2 in the renal cortex of human prorenin receptor gene-transgenic rats. Kidney Int. 2006, 70:641-646.
28. Kaneshiro Y., Ichihara A., Sakoda M., Takemitsu T., Nabi A.H., Uddin M.N., Nakagawa T., Nishiyama A., Suzuki F., Inagami T., Itoh H. Slowly progressive, angiotensin II-independent glomerulosclerosis in human (pro)renin receptor-transgenic rats. J. Am. Soc. Nephrol. 2007, 18:1789-1795.
29. Kang Y.S., Lee M.H., Song H.K., Hyun Y.Y., Cha J.J., Ko G.J., Kim S.H., Lee J.E., Han J.Y., Cha D.R. Aliskiren improves insulin resistance and ameliorates diabetic vascular complications in db/db mice 2010, Nephrol. Dial. Transplant.
30. Kato T., Kageshima A., Suzuki F., Park E.Y. Expression and purification of human (pro)renin receptor in insect cells using baculovirus expression system. Protein Expr. Purif. 2008, 58:242-248.
31. Kinouchi K., Ichihara A., Sano M., Sun-Wada G.H., Wada Y., Kurauchi-Mito A., Bokuda K., Narita T., Oshima Y., Sakoda M., Tamai Y., Sato H., Fukuda K., Itoh H. The (pro)renin receptor/ATP6AP2 is essential for vacuolar H+-ATPase assembly in murine cardiomyocytes. Circ. Res. 2010, 107:30-34.
32. Kobayashi K., Ohno Y., Takenaka T., Ikeda N., Okada H., Kanno Y., Suzuki H. Telmisartan lowers home blood pressure and improves insulin resistance without correlation between their changes. Clin. Exp. Hypertens. 2011, 33:100-105.
33. Kobori H., Nangaku M., Navar L.G., Nishiyama A. The intrarenal renin-angiotensin system: from physiology to the pathobiology of hypertension and kidney disease. Pharmacol. Rev. 2007, 59:251-287.
34. Krebs C., Weber M., Steinmetz O., Meyer-Schwesinger C., Stahl R., Danser A.H., Garrelds I., van Goor H., Nguyen G., Muller D., Wenzel U. Effect of (pro)renin receptor inhibition by a decoy peptide on renal damage in the clipped kidney of Goldblatt rats. Kidney Int. 2008, 74:823-824.
35. Lastra G., Habibi J., Whaley-Connell A.T., Manrique C., Hayden M.R., Rehmer J., Patel K., Ferrario C., Sowers J.R. Direct renin inhibition improves systemic insulin resistance and skeletal muscle glucose transport in a transgenic rodent model of tissue renin overexpression. Endocrinology 2009, 150:2561-2568.
36. Ludwig J., Kerscher S., Brandt U., Pfeiffer K., Getlawi F., Apps D.K., Schagger H. Identification and characterization of a novel 9.2-kDa membrane sector-associated protein of vacuolar proton-ATPase from chromaffin granules. J. Biol. Chem. 1998, 273:10939-10947.
37. Matavelli L.C., Huang J., Siragy H.M. (Pro)renin receptor contributes to diabetic nephropathy by enhancing renal inflammation. Clin. Exp. Pharmacol. Physiol. 2010, 37:277-282.
38. Mercure C., Prescott G., Lacombe M.J., Silversides D.W., Reudelhuber T.L. Chronic increases in circulating prorenin are not associated with renal or cardiac pathologies. Hypertension 2009, 53:1062-1069.
39. Mizuguchi Y., Ichihara A., Seki Y., Sakoda M., Kurauchi-Mito A., Narita T., Kinouchi K., Bokuda K., Itoh H. Renoprotective effects of mineralocorticoid receptor blockade in heminephrectomized (pro)renin receptor transgenic rats. Clin. Exp. Pharmacol. Physiol. 2010, 37:569-573.
40. Muller D.N., Klanke B., Feldt S., Cordasic N., Hartner A., Schmieder R.E., Luft F.C., Hilgers K.F. (Pro)renin receptor peptide inhibitor "handle-region" peptide does not affect hypertensive nephrosclerosis in Goldblatt rats. Hypertension 2008, 51:676-681.
41. Nabi A.H., Kageshima A., Uddin M.N., Nakagawa T., Park E.Y., Suzuki F. Binding properties of rat prorenin and renin to the recombinant rat renin/prorenin receptor prepared by a baculovirus expression system. Int. J. Mol. Med. 2006, 18:483-488.
42. Nagai Y., Ichihara A., Nakano D., Kimura S., Pelisch N., Fujisawa Y., Hitomi H., Hosomi N., Kiyomoto H., Kohno M., Ito H., Nishiyama A. Possible contribution of the non-proteolytic activation of prorenin to the development of insulin resistance in fructose-fed rats. Exp. Physiol. 2009, 94:1016-1023.
43. Nguyen G., Danser A.H. The (pro)renin receptor: therapeutic consequences. Expert Opin. Investig. Drugs 2006, 15:1131-1135.
44. Nguyen G., Danser A.H. Prorenin and (pro)renin receptor: a review of available data from in vitro studies and experimental models in rodents. Exp. Physiol. 2008, 93:557-563.
45. Nguyen G., Muller D.N. The biology of the (pro)renin receptor. J. Am. Soc. Nephrol. 2010, 21:18-23.
46. Nguyen G., Delarue F., Burckle C., Bouzhir L., Giller T., Sraer J.D. Pivotal role of the renin/prorenin receptor in angiotensin II production and cellular responses to renin. J. Clin. Invest. 2002, 109:1417-1427.
47. Nishi T., Forgac M. The vacuolar (H+)-ATPases-nature's most versatile proton pumps. Nat. Rev. Mol. Cell Biol. 2002, 3:94-103.
48. Nurun N.A., Uddin N.M., Nakagawa T., Iwata H., Ichihara A., Inagami T., Suzuki F. Role of "handle" region of prorenin prosegment in the non-proteolytic activation of prorenin by binding to membrane anchored (pro)renin receptor. Front Biosci. 2007, 12:4810-4817.
49. Oshima Y., Kinouchi K., Ichihara A., Sakoda M., Kurauchi-Mito A., Bokuda K., Narita T., Kurosawa H., Sun-Wada G.H., Wada Y., Yamada T., Takemoto M., Saleem M.A., Quaggin S.E., Itoh H. Prorenin receptor is essential for normal podocyte structure and function. J. Am. Soc. Nephrol. 2011, 22:2203-2212.
50. Ott C., Schneider M.P., Delles C., Schlaich M.P., Hilgers K.F., Schmieder R.E. Association of (pro)renin receptor gene polymorphism with blood pressure in Caucasian men. Pharmacogenet. Genomics 2011, 21:347-349.
51. Peters B., Grisk O., Becher B., Wanka H., Kuttler B., Ludemann J., Lorenz G., Rettig R., Mullins J.J., Peters J. Dose-dependent titration of prorenin and blood pressure in Cyp1a1ren-2 transgenic rats: absence of prorenin-induced glomerulosclerosis. J. Hypertens. 2008, 26:102-109.
52. Prescott G., Silversides D.W., Reudelhuber T.L. Tissue activity of circulating prorenin. Am. J. Hypertens. 2002, 15:280-285.
53. Rafiq K., Nagai Y., Nakano D. Prorenin/renin and insulin resistance. Front Biosci (Elite Ed) 2010, 2:1143-1146.
54. Rafiq K., Hitomi H., Nakano D., Ichihara A., Nishiyama A. Possible involvement of the (pro)renin receptor-dependent system in the development of insulin resistance. Front. Biosci. (Schol Ed) 2011, 3:1478-1485.
55. Ramser J., Abidi F.E., Burckle C.A., Lenski C., Toriello H., Wen G., Lubs H.A., Engert S., Stevenson R.E., Meindl A., Schwartz C.E., Nguyen G. A unique exonic splice enhancer mutation in a family with X-linked mental retardation and epilepsy points to a novel role of the renin receptor. Hum. Mol. Genet. 2005, 14:1019-1027.
56. Riediger F., Quack I., Qadri F., Hartleben B., Park J.K., Potthoff S.A., Sohn D., Sihn G., Rousselle A., Fokuhl V., Maschke U., Purfurst B., Schneider W., Rump L.C., Luft F.C., Dechend R., Bader M., Huber T.B., Nguyen G., Muller D.N. Prorenin receptor is essential for podocyte autophagy and survival. J. Am. Soc. Nephrol. 2011, 22:2193-2202.
57. Samad F., Yamamoto K., Pandey M., Loskutoff D.J. Elevated expression of transforming growth factor-beta in adipose tissue from obese mice. Mol. Med. 1997, 3:37-48.
58. Saris J.J., Hoen P.A., Garrelds I.M., Dekkers D.H., den Dunnen J.T., Lamers J.M., Jan Danser A.H. Prorenin induces intracellular signaling in cardiomyocytes independently of angiotensin II. Hypertension 2006, 48:564-571.
59. Shiuchi T., Cui T.X., Wu L., Nakagami H., Takeda-Matsubara Y., Iwai M., Horiuchi M. ACE inhibitor improves insulin resistance in diabetic mouse via bradykinin and NO. Hypertension 2002, 40:329-334.
60. Shiuchi T., Iwai M., Li H.S., Wu L., Min L.J., Li J.M., Okumura M., Cui T.X., Horiuchi M. Angiotensin II type-1 receptor blocker valsartan enhances insulin sensitivity in skeletal muscles of diabetic mice. Hypertension 2004, 43:1003-1010.
61. Sun-Wada G.H., Toyomura T., Murata Y., Yamamoto A., Futai M., Wada Y. The a3 isoform of V-ATPase regulates insulin secretion from pancreatic beta-cells. J. Cell Sci. 2006, 119:4531-4540.
62. Susic D., Zhou X., Frohlich E.D., Lippton H., Knight M. Cardiovascular effects of prorenin blockade in genetically spontaneously hypertensive rats on normal and high-salt diet. Am. J. Physiol. Heart Circ. Physiol. 2008, 295:H1117-H1121.
63. Suzuki F., Hayakawa M., Nakagawa T., Nasir U.M., Ebihara A., Iwasawa A., Ishida Y., Nakamura Y., Murakami K. Human prorenin has "gate and handle" regions for its non-proteolytic activation. J. Biol. Chem. 2003, 278:22217-22222.
64. Takahashi N., Li F., Hua K., Deng J., Wang C.H., Bowers R.R., Bartness T.J., Kim H.S., Harp J.B. Increased energy expenditure, dietary fat wasting, and resistance to diet-induced obesity in mice lacking renin. Cell Metab. 2007, 6:506-512.
65. Uddin M.N., Nabi A.H., Nakagawa T., Ichihara A., Inagami T., Suzuki F. Non-proteolytic activation of prorenin: activation by (pro)renin receptor and its inhibition by a prorenin prosegment, "decoy peptide". Front. Biosci. 2008, 13:745-753.
66. Uehara S., Tsuchida M., Kanno T., Sasaki M., Nishikibe M., Fukamizu A. Late-onset obesity in mice transgenic for the human renin gene. Int. J. Mol. Med. 2003, 11:723-727.
67. Yang G., Merrill D.C., Thompson M.W., Robillard J.E., Sigmund C.D. Functional expression of the human angiotensinogen gene in transgenic mice. J. Biol. Chem. 1994, 269:32497-32502.
68. Zhang J., Noble N.A., Border W.A., Owens R.T., Huang Y. Receptor-dependent prorenin activation and induction of PAI-1 expression in vascular smooth muscle cells. Am. J. Physiol. Endocrinol. Metab. 2008, 295:E810-819.